Melanoma Flashcards

1
Q

What are the risk factors for melanoma?

A

unprotected sun exposure, fair skin, dysplastic naevi, immunosuppression, family history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What genes increase risk of melanoma?

A

CDKN2A, CDK4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the prognostic factors in melanoma?

A

tumour thickness, mitotic rate, ulceration, primary tumour location, older age, male, lymph nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the treatment for stage 0 melanoma?

A

surgical resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the management for stage I melanoma?

A

surgical resection, consider sentinel LN biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the management for stage II melanoma?

A

surgical resection, sentinel LN bx, consider adjuvant RTx and systemic Tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the management for stage III melanoma?

A

surgical resection, nodal dissection, consider adjuvant RTx and systemic Tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the most important mutation in melanoma?

A

BRAF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the BRAF inhibitors?

A

vemurafenib and dabrafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What percentage of patients on BRAF inhibitors develop resistance?

A

80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How do you prevent BRAF inhibitor resistance?

A

use in combination with a MEK inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the common side effects of BRAF inhibitor and MEK inhibitors?

A

fever, rash, pruritus, photosensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the immunotherapies available for melanoma?

A

Anti-CTLA4 (ipilimumab), PD-1 inhibitors (pembrolizumab, nivolumab)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which is better anti-CTLA4 or PD-1 inhibitors?

A

PD-1 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which has better toxicity profile anti-CTLA4 or PD-1 inhibitors?

A

PD-1 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the common sites of immune related adverse events?

A

skin, GI, liver, thyroid, adrenal, lung

17
Q

What is the treatment for immune related adverse events?

A

if mild treat symptomatically, if moderate - oral steroids, if severe - high dose IV corticosteroids and stop immunotherapy

18
Q

What are the most common cutaneous immune related adverse events?

A

maculopapular rash, steven johnson, sweet syndrome, bullous pemphigoid

19
Q

What is the treatment for asymptomatic endocrinopathies?

A

monitoring

20
Q

Should adjuvant treatment be used in stage III melanoma?

A

yes - evidence for improved survival with BRAF/MEK inhibitors and anti-CTLA4 inhibitors